263 related articles for article (PubMed ID: 10362320)
21. Oxygen levels in normal and previously irradiated human skin as assessed by EF5 binding.
Evans SM; Schrlau AE; Chalian AA; Zhang P; Koch CJ
J Invest Dermatol; 2006 Dec; 126(12):2596-606. PubMed ID: 16810299
[TBL] [Abstract][Full Text] [Related]
22. 2-Nitroimidazole (EF5) binding predicts radiation resistance in individual 9L s.c. tumors.
Evans SM; Jenkins WT; Joiner B; Lord EM; Koch CJ
Cancer Res; 1996 Jan; 56(2):405-11. PubMed ID: 8542599
[TBL] [Abstract][Full Text] [Related]
23. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide] : analysis of drug adducts by fluorescent antibodies vs bound radioactivity.
Koch CJ; Evans SM; Lord EM
Br J Cancer; 1995 Oct; 72(4):869-74. PubMed ID: 7547233
[TBL] [Abstract][Full Text] [Related]
24. Repetitive intermittent hypoxia-ischemia and brain damage in neonatal rats.
Nagata N; Saji M; Ito T; Ikeno S; Takahashi H; Terakawa N
Brain Dev; 2000 Aug; 22(5):315-20. PubMed ID: 10891639
[TBL] [Abstract][Full Text] [Related]
25. Patterns and levels of hypoxia in head and neck squamous cell carcinomas and their relationship to patient outcome.
Evans SM; Du KL; Chalian AA; Mick R; Zhang PJ; Hahn SM; Quon H; Lustig R; Weinstein GS; Koch CJ
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1024-31. PubMed ID: 17967299
[TBL] [Abstract][Full Text] [Related]
26. [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure.
Dolbier WR; Li AR; Koch CJ; Shiue CY; Kachur AV
Appl Radiat Isot; 2001 Jan; 54(1):73-80. PubMed ID: 11144255
[TBL] [Abstract][Full Text] [Related]
27. Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma.
Koch CJ; Scheuermann JS; Divgi C; Judy KD; Kachur AV; Freifelder R; Reddin JS; Karp J; Stubbs JB; Hahn SM; Driesbaugh J; Smith D; Prendergast S; Evans SM
Eur J Nucl Med Mol Imaging; 2010 Nov; 37(11):2048-59. PubMed ID: 20585774
[TBL] [Abstract][Full Text] [Related]
28. 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model.
Chitneni SK; Bida GT; Yuan H; Palmer GM; Hay MP; Melcher T; Wilson WR; Zalutsky MR; Dewhirst MW
J Nucl Med; 2013 Aug; 54(8):1339-46. PubMed ID: 23740105
[TBL] [Abstract][Full Text] [Related]
29. Importance of antibody concentration in the assessment of cellular hypoxia by flow cytometry: EF5 and pimonidazole.
Koch CJ
Radiat Res; 2008 Jun; 169(6):677-88. PubMed ID: 18494550
[TBL] [Abstract][Full Text] [Related]
30. Hypoxia-inducible factor-1alpha is an intrinsic marker for hypoxia in cervical cancer xenografts.
Vukovic V; Haugland HK; Nicklee T; Morrison AJ; Hedley DW
Cancer Res; 2001 Oct; 61(20):7394-8. PubMed ID: 11606368
[TBL] [Abstract][Full Text] [Related]
31. EF5 binding and clinical outcome in human soft tissue sarcomas.
Evans SM; Fraker D; Hahn SM; Gleason K; Jenkins WT; Jenkins K; Hwang WT; Zhang P; Mick R; Koch CJ
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):922-7. PubMed ID: 16458778
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] in human patients: implications for hypoxia measurements in vivo by 2-nitroimidazoles.
Koch CJ; Hahn SM; Rockwell K; Covey JM; McKenna WG; Evans SM
Cancer Chemother Pharmacol; 2001 Sep; 48(3):177-87. PubMed ID: 11592338
[TBL] [Abstract][Full Text] [Related]
33. Changes in adenosine receptors in the neonatal rat brain following hypoxic ischemia.
Adén U; Lindström K; Bona E; Hagberg H; Fredholm BB
Brain Res Mol Brain Res; 1994 Jun; 23(4):354-8. PubMed ID: 8090076
[TBL] [Abstract][Full Text] [Related]
34. Tracer level electrophilic synthesis and pharmacokinetics of the hypoxia tracer [(18)F]EF5.
Eskola O; Grönroos TJ; Forsback S; Tuomela J; Komar G; Bergman J; Härkönen P; Haaparanta M; Minn H; Solin O
Mol Imaging Biol; 2012 Apr; 14(2):205-12. PubMed ID: 21448777
[TBL] [Abstract][Full Text] [Related]
35. Hypoxia and VEGF mRNA expression in human tumors.
Ziemer LS; Koch CJ; Maity A; Magarelli DP; Horan AM; Evans SM
Neoplasia; 2001; 3(6):500-8. PubMed ID: 11774032
[TBL] [Abstract][Full Text] [Related]
36. Co-localization of hypoxia and apoptosis in irradiated and untreated HCT116 human colon carcinoma xenografts.
Koch CJ; Chasan JE; Jenkins WT; Chan CY; Laughlin KM; Evans SM
Adv Exp Med Biol; 1998; 454():611-8. PubMed ID: 9889941
[TBL] [Abstract][Full Text] [Related]
37. The calpain proteolytic system in neonatal hypoxic-ischemia.
Blomgren K; McRae A; Elmered A; Bona E; Kawashima S; Saido TC; Ono T; Hagberg H
Ann N Y Acad Sci; 1997 Oct; 825():104-19. PubMed ID: 9369979
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the Hypoxia PET Tracer (18)F-EF5 to Immunohistochemical Marker EF5 in 3 Different Human Tumor Xenograft Models.
Chitneni SK; Bida GT; Zalutsky MR; Dewhirst MW
J Nucl Med; 2014 Jul; 55(7):1192-7. PubMed ID: 24854792
[TBL] [Abstract][Full Text] [Related]
39. Role of excitatory amino acid transporter 1 in neonatal rat neuronal damage induced by hypoxia-ischemia.
Tao F; Lu SD; Zhang LM; Huang YL; Sun FY
Neuroscience; 2001; 102(3):503-13. PubMed ID: 11226689
[TBL] [Abstract][Full Text] [Related]
40. Detection of tumour hypoxia: comparison between EF5 adducts and [18F]EF3 uptake on an individual mouse tumour basis.
Mahy P; De Bast M; Gillart J; Labar D; Grégoire V
Eur J Nucl Med Mol Imaging; 2006 May; 33(5):553-6. PubMed ID: 16523307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
